TY - JOUR
T1 - Changing trends in the treatment of dry-eye disease
AU - Dogru, Murat
AU - Nakamura, Masatsugu
AU - Shimazaki, Jun
AU - Tsubota, Kazuo
PY - 2013/12
Y1 - 2013/12
N2 - Introduction: Dry eye is a visually disabling disease encountered in many countries with a wide variation of treatment practices all over the world. On that front, the 2007 Report of the International Dry Eye WorkShop (DEWS) reviewed the current knowledge on all aspects of dry-eye disease (DED), in an evidence-based manner, and outlined the trends and recommendations in the treatment of DED on the basis of disease severity. Areas covered: This review mainly focuses on treatments for DED based on severity as recommended in the DEWS report, particularly artificial eye drops, hyaluronate sodium eye drops, autologous serum, anti-inflammatory eye drops including cyclosporine and steroids, and mucin secretagogues. New dry-eye treatment modalities in current trials outlined on the clinicaltrial.gov site are also outlined. Expert opinion: Further investigations into the mechanism of action of the new mucin and tear secretagogues which have been suggested to have anti-inflammatory properties will enrich our understanding in relation to relevant ocular surface responses after treatment with these new agents.
AB - Introduction: Dry eye is a visually disabling disease encountered in many countries with a wide variation of treatment practices all over the world. On that front, the 2007 Report of the International Dry Eye WorkShop (DEWS) reviewed the current knowledge on all aspects of dry-eye disease (DED), in an evidence-based manner, and outlined the trends and recommendations in the treatment of DED on the basis of disease severity. Areas covered: This review mainly focuses on treatments for DED based on severity as recommended in the DEWS report, particularly artificial eye drops, hyaluronate sodium eye drops, autologous serum, anti-inflammatory eye drops including cyclosporine and steroids, and mucin secretagogues. New dry-eye treatment modalities in current trials outlined on the clinicaltrial.gov site are also outlined. Expert opinion: Further investigations into the mechanism of action of the new mucin and tear secretagogues which have been suggested to have anti-inflammatory properties will enrich our understanding in relation to relevant ocular surface responses after treatment with these new agents.
KW - Artificial eye drops
KW - Autologous serum
KW - Dry-eye disease
KW - Mucin secretagogues
KW - Tear secretagogues
UR - http://www.scopus.com/inward/record.url?scp=84887798602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887798602&partnerID=8YFLogxK
U2 - 10.1517/13543784.2013.838557
DO - 10.1517/13543784.2013.838557
M3 - Review article
C2 - 24088227
AN - SCOPUS:84887798602
SN - 1354-3784
VL - 22
SP - 1581
EP - 1601
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 12
ER -